Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 16/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9271328 | 0.90 | TBXAS1 (0.69) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| Dazoxiben SCHEMBL11554 | 0.87 | TBXAS1 (1.00) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL8690701 | 0.86 | TBXAS1 (0.75) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| Dazoxiben SCHEMBL564080 | 0.86 | TBXAS1 (1.00) | TBXAS1MEN1LMNAKMT2A | |
| Dazoxiben SCHEMBL4427771 | 0.86 | TBXAS1 (0.97) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL3005716 | 0.86 | TBXAS1 (1.00) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL10750647 | 0.86 | TBXAS1 (1.00) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL10751448 | 0.85 | TBXAS1 (1.00) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL10750950 | 0.85 | TBXAS1 (1.00) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL8685263 | 0.84 | TBXAS1 (0.88) | TBXAS1MEN1LMNAKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | claimed |
| US-7495029-B2 | Prodrugs of (2R)-2-propyloctanoic acid for the treatment of stroke | MERCK & CO., INC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080132488-A1 | Prodrugs of (2R)-2-Propyloctanoic Acid For the Treatment of Stroke | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132488-A1 | Prodrugs of (2R)-2-Propyloctanoic Acid For the Treatment of Stroke | APEH, HCAR2, PTGDR | TBXAS1 694/4885MEN1 4661/4885LMNA 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.